Bihel Frédéric
Faculty of Pharmacy, University of Strasbourg, CNRS, UMR7200, 67400 Illkirch Graffenstaden, France.
Future Med Chem. 2016;8(3):339-54. doi: 10.4155/fmc.15.186. Epub 2016 Feb 22.
Opioid analgesics continue to be the mainstay of pharmacologic treatment of moderate to severe pain. Many patients, particularly those suffering from chronic pain, require chronic high-dose analgesic therapy. Achieving clinical efficacy and tolerability of such treatment regimens is hampered by the appearance of opioid-induced side effects such as tolerance, hyperalgesia and withdrawal syndrome. Among the therapeutic options to improve the opioid effectiveness, this current review focuses on strategies combining opioids to other drugs that can modulate opioid-mediated effects. We will discuss about experimental evidences reported for several potential opioid adjuvants, including N-methyl-D-aspartate receptor antagonists, 5-HT7 agonists, sigma-1 antagonists, I2-R ligands, cholecystokinin antagonists, neuropeptide FF-R antagonists and toll-like receptor 4 antagonists.
阿片类镇痛药仍然是中重度疼痛药物治疗的主要手段。许多患者,尤其是那些患有慢性疼痛的患者,需要长期高剂量镇痛治疗。阿片类药物引起的副作用,如耐受性、痛觉过敏和戒断综合征的出现,阻碍了此类治疗方案临床疗效和耐受性的实现。在提高阿片类药物有效性的治疗选择中,本综述重点关注将阿片类药物与其他可调节阿片类介导效应的药物联合使用的策略。我们将讨论几种潜在阿片类佐剂的实验证据,包括N-甲基-D-天冬氨酸受体拮抗剂、5-HT7激动剂、σ-1拮抗剂、I2-R配体、胆囊收缩素拮抗剂、神经肽FF-R拮抗剂和Toll样受体4拮抗剂。